USD
( +0.00%
At Close (As of Jan 1, 1970)
$45.23M
Market Cap
-
P/E Ratio
-1.13
EPS
$2.41
52 Week High
$1.02
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Total Assets | $77M |
| Total Current Assets | $75M |
| Cash And Cash Equivalents At Carrying Value | $73M |
| Cash And Short Term Investments | $73M |
| Inventory | - |
| Current Net Receivables | - |
| Total Non Current Assets | $2.4M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $1.6M |
| Other Non Current Assets | - |
| Total Liabilities | $44M |
| Total Current Liabilities | $8.1M |
| Current Accounts Payable | $7.6M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $580K |
| Total Non Current Liabilities | $36M |
| Capital Lease Obligations | $1.6M |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $1.6M |
| Other Current Liabilities | -$580K |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $33M |
| Treasury Stock | - |
| Retained Earnings | -$376M |
| Common Stock | $31K |
| Common Stock Shares Outstanding | $30M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$33M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $811K |
| Capital Expenditures | $11K |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | -$11K |
| Cashflow From Financing | $29M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$38M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Actinium Pharmaceuticals, Inc. is a leading clinical-stage biopharmaceutical firm focused on developing cutting-edge therapies for bone marrow transplantation and adoptive cell therapies, with a primary emphasis on hematologic malignancies. Based in New York, the company is advancing its proprietary antibody-radionuclide conjugate platform, aimed at improving patient outcomes in both transplantation and cancer care. With a promising pipeline of therapeutic candidates and strategic collaborations, Actinium is well-positioned to tackle significant unmet medical needs in the oncology sector, making it a compelling prospect for institutional investors seeking innovation in biopharmaceuticals.